



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  C12N 5/02		A1	(11) International Publication Number: <b>WO 94/02592</b>  (43) International Publication Date: 3 February 1994 (03.02.94)																											
<p>(21) International Application Number: PCT/GB93/01572</p> <p>(22) International Filing Date: 26 July 1993 (26.07.93)</p> <p>(30) Priority data: 9215834.4 24 July 1992 (24.07.92) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): CELLTECH LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>) : FIELD, Raymond, Paul [GB/GB]; 17 Johnson Close, Mossley, Congleton, Cheshire CW12 3TQ (GB).</p> <p>(74) Agent: HALLYBONE, Huw, George; Carpmaels &amp; Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> <i>With international search report.</i></p>																												
<p><b>(54) Title:</b> ANIMAL CELL CULTURE</p> <p><b>(57) Abstract</b></p> <p>An animal cell culture medium is described which contains 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof to support the growth of animal cells, particularly in agitated cell culture at low iron concentrations.</p> <table border="1"> <caption>Data for Bar Chart (approximate values)</caption> <thead> <tr> <th>Chelator</th> <th>-TFN (1 μg/ml)</th> <th>+TFN (1 μg/ml)</th> </tr> </thead> <tbody> <tr> <td>-TFN</td> <td>~1.5</td> <td>~1.5</td> </tr> <tr> <td>3 μM</td> <td>~1.5</td> <td>~11.0</td> </tr> <tr> <td>0.3 μM</td> <td>~1.5</td> <td>~11.5</td> </tr> <tr> <td>0.03 μM</td> <td>~1.5</td> <td>~11.5</td> </tr> </tbody> </table> <p><b>CHELATOR CONC.</b> Controls do not contain chelator TFN = TRANSFERRIN</p> <table border="1"> <caption>Data for Bar Chart (approximate values)</caption> <thead> <tr> <th>Addition</th> <th>Max. Cells / ml (x 10^-5)</th> </tr> </thead> <tbody> <tr> <td>ACETYLACETONE</td> <td>~4.0</td> </tr> <tr> <td>PICOLINIC ACID</td> <td>~5.0</td> </tr> <tr> <td>TROPOLONE</td> <td>~13.5</td> </tr> <tr> <td>TRANSFERRIN</td> <td>~10.5</td> </tr> <tr> <td>NO ADDITIONS</td> <td>~2.0</td> </tr> </tbody> </table>				Chelator	-TFN (1 μg/ml)	+TFN (1 μg/ml)	-TFN	~1.5	~1.5	3 μM	~1.5	~11.0	0.3 μM	~1.5	~11.5	0.03 μM	~1.5	~11.5	Addition	Max. Cells / ml (x 10^-5)	ACETYLACETONE	~4.0	PICOLINIC ACID	~5.0	TROPOLONE	~13.5	TRANSFERRIN	~10.5	NO ADDITIONS	~2.0
Chelator	-TFN (1 μg/ml)	+TFN (1 μg/ml)																												
-TFN	~1.5	~1.5																												
3 μM	~1.5	~11.0																												
0.3 μM	~1.5	~11.5																												
0.03 μM	~1.5	~11.5																												
Addition	Max. Cells / ml (x 10^-5)																													
ACETYLACETONE	~4.0																													
PICOLINIC ACID	~5.0																													
TROPOLONE	~13.5																													
TRANSFERRIN	~10.5																													
NO ADDITIONS	~2.0																													

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## ANIMAL CELL CULTURE

5

### FIELD OF THE INVENTION

This invention relates to improvements in animal cell culture, particularly to improvements in methods for growing animal cells and nutrient media therefor.

10

### BACKGROUND TO THE INVENTION

15      The use of animal cell culture for the mass production of cell products such as immunoglobulins, hormones and enzymes is becoming increasingly important from a commercial point of view, and currently there is considerable effort devoted to the development of cell culture techniques for the optimisation of the large scale production of these materials.

20

25      Animal cells in culture require a basal nutrient mixture of salts, sugars, amino acids and vitamins. Usually the mixture is supplemented with a biological fluid or extract, in the absence of which most cells lose viability or fail to proliferate. The most commonly used supplement is serum.

25

The use of supplements, however, is not very satisfactory, since their generally undefined nature, and the variations that can exist between batches of a given type, can affect the success and reproducibility of a culture. There have thus been numerous attempts to identify the active factors in supplements such as serum, with a view to providing a better defined medium to support the growth of cells in culture. To date, this approach has met with limited success, largely due to the complex nature of biological supplements and the very small amounts of active factors that they contain.

35

A number of supplement-free media have been described, however, some of which are available commercially [see for example Murakami *et al.*,

Proc.Natl. Acad. Sci. USA 79, 1158-1162 (1982); Darfler *et al.*, Exp. Cell Res. 138, 287-295 (1982) and International Patent Specification No. WO 90/03430].

5      Supplement-free media generally contain a complex mixture of amino acids, salts, vitamins, trace elements, carbohydrates and other growth supporting components such as albumin, insulin, glutamine, transferrin, ferritin and ethanolamine [see for example US Patent Specification No. 4816401]. When cultured in such media, animal cells remain viable for a  
10     finite period of time, until one or more essential nutrients in the medium become exhausted. At such time the medium may be supplemented with a feed containing one or more energy sources and one or more amino acids [see for example International Patent Specification No. WO 87/00195]. In this way the culture may be prolonged to increase yield of  
15     cells or cell products.

Metal ions, especially ferrous and ferric ions, are essential for animal cell metabolism, and are present in culture media as components of undefined supplements such as serum, or as components of salts and trace elements included in supplement-free media. Cellular demand for metal ions can become high in animal cell culture, especially when high cell densities are reached and in practice this means that metal ions need to be made continuously available in culture to support the growth and viability of cells. To achieve this in a supplement-free medium high concentrations of a simple salt of the metal can be used, but it is often necessary for the metal to be in a chelated form in the medium to facilitate cellular uptake of the metal and/or to avoid the solubility and toxicity problems which can be associated with high metal ion concentrations.

30     To supply sufficient iron to cells growing in supplement-free media, simple or complex iron salts such as ferrous sulphate, ferric chloride, ferric nitrate or ferric ammonium citrate have been used, where necessary often in combination with a chelating agent. Particular iron chelating agents which have been used in cell culture include the natural proteins transferrin and ferritin; organic acids such as citric acid, iminodiacetic acid and gluconic acid; pyridoxal isonicotinoyl hydrazone; and aurin tricarboxylic acid.

A number of factors are important in selecting an iron chelating agent for general use in supplement-free media for animal cell culture. Thus, the chelating agent must have an appropriate binding affinity for the iron and be able to transport it efficiently across the cell membrane. It must also 5 be cheap, readily available and non-toxic. Increasingly importantly, the chelating agent should be of synthetic, not animal, origin to avoid any possible unwanted contamination of any desired cell product and a consequent increase in the cost of recovery of a pure product. None of the above-mentioned chelating agents meets all of these criteria.

10

### SUMMARY OF THE INVENTION

We have now found that 2-hydroxy-2,4,6-cycloheptatrien-1-one meets all 15 of these criteria and may be used advantageously in animal cell culture to support the growth of cells. In particular, we have found that its use can support growth in agitated cell culture, where it is necessary to use low iron concentration to avoid toxicity problems, and where the use of other recognised chelating agents such as citrate and gluconate has failed. We 20 have used this discovery to develop a medium and a process for the growth of animal cells.

Thus, according to one aspect of the invention, we provide a nutrient animal cell culture medium comprising assimilable sources of carbon, 25 nitrogen, amino acids, iron and other inorganic ions, trace elements and optionally lipids and growth promoters or regulators in admixture with 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof.

30 **DETAILED DESCRIPTION OF THE INVENTION**

In general the nutrient medium may be any known basal medium or variants thereof which will support the continuous growth of animal cells and/or sustain them during a stationary phase, to which 2-hydroxy-2,4,6-35 cycloheptatrien-1-one [hereinafter sometimes referred to as tropolone] or a derivative thereof has been added. Known basal media and variants thereof include for example Dulbecco's Modification of Eagle's Medium (DMEM), Iscove Modified Dulbecco's Medium, Ham's Medium, Roswell

Park Memorial Institute Medium (RPMI) and Fischer's Medium, or those described by Hu *et al* in Biotechnol. Bioeng. (1985), 27, 585-595; by Crespi and Thilly in Biotechnol. Bioeng. (1981), 23, 983-993, and by Van Wezel in Dev. Biol. Stand. (1977), 37, 143-147. In one preferred aspect, 5 the medium is a protein-free medium.

The tropolone or derivative thereof is generally present in the medium according to the invention at a concentration sufficient to support the growth and viability of the cells. The exact concentration may vary 10 depending on the cell line in use and the other media components present, but may be easily determined using preliminary small scale tests in accordance with conventional practice. Thus, for example, for any chosen medium cells may be cultured on a small scale in the presence of a range of tropolone concentrations and the optimum concentration 15 determined by observing the effect of different concentrations on cell growth and viability.

In general, the tropolone or tropolone derivative will be present in an excess molar concentration to the iron present in the medium for example 20 at a molar ratio of around 5 to 1 to around 70 to 1, for example around 10 to 1 to around 70 to 1. Thus for example where the iron concentration in the medium is around 0.3 $\mu$ M, the tropolone or derivative thereof may be employed at a concentration of around 1.5 $\mu$ M to around 20 $\mu$ M, e.g. around 3 $\mu$ M to around 20 $\mu$ M. The iron may be present as ferrous or ferric 25 ions, for example resulting from the use of simple or complex iron salts in the medium such as ferrous sulphate, ferric chloride, ferric nitrate or in particular ferric ammonium citrate.

Tropolone derivatives for use in the media according to the invention in 30 general are those derivatives which are capable of chelating ferrous or ferric ions. Particular derivatives include those wherein one or more ring carbon atoms of tropolone are substituted by aliphatic, aromatic or heteroaromatic groups, e.g. by alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl or 35 heteroaralkynyl groups. Tropolone or derivatives thereof are either commercially available [e.g. from the Aldrich Chemical Co.] or may be prepared using known literature procedures.

The media according to the invention may be prepared by appropriate mixture of individual components using conventional procedures and may either be provided in liquid form, or in dry form for reconstitution before use with an appropriate buffer, e.g. a bicarbonate buffer. In preparing the media according to the invention, it is advisable to avoid the use of a concentrated liquid mixture of tropolone and iron.

The media according to the invention may be used to culture animal cells. Thus according to a further aspect of the invention we provide a nutrient animal cell culture medium comprising assimilable sources of carbon, nitrogen, amino acids, iron and other inorganic ions, trace elements and optionally lipids and growth promoters or regulators in admixture with 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof for the continuous growth of animal cells.

The media according to the invention are particularly suitable for the continuous growth of animal cells in an agitated culture, particularly at a low iron concentration, e.g. at an iron concentration of around 0.3 $\mu$ M.

The animal cells which may be cultured according to the invention may be for example genetically engineered cells, lymphoid cells e.g. myeloma cells, or hybridoma or other fused cells. Particular cell types include cells of human, rat, mouse or hamster origin. The medium according to the invention is particularly suitable for use with lymphoid cells, especially myeloma cells, particularly of mouse origin, especially NS/O cells.

The media according to the invention may be used to culture animal cells to obtain an animal cell product. Thus according to a further aspect of the invention, we provide a process for obtaining an animal cell product by cell culture which comprises the steps of (1) culturing animal cells which produce said product in a nutrient culture medium comprising assimilable sources of carbon, nitrogen, amino acids, iron and other inorganic ions, trace elements and optionally lipids and growth promoters or regulators in admixture with 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof, (2) continuing the culture until said product accumulates and (3) recovering said product.

Cell products which may be obtained according to the invention include any products which are produced by cultured animal cells. Typical products include polypeptides and proteins, for example immunoglobulins such as monoclonal and recombinant antibodies and fragments thereof,

5 hormones such as erythropoietin and growth hormone, e.g. human growth hormone, lymphokines such as interferon, interleukins such as interleukin 2, 4, 5 and 6 and industrially and therapeutically useful enzymes such as tissue plasminogen activator.

10 In the process according to the invention, the animal cells may generally be cultured in suspension in the culture medium in a suitable culture vessel, for example a stirred tank or airlift fermenter, using known culture techniques.

15 Thus, for example, a seed culture of suitable cells, obtained by conventional techniques, may be used to inoculate the culture medium. In general, the number of cells used for inoculation will be in the range  $1 \times 10^5$  to  $5 \times 10^5$  cells ml<sup>-1</sup> or less. The cells are then cultured until a desired cell density is reached and/or until sufficient product has accumulated.

20 The production of the desired products during the culture may be monitored using any appropriate assay for the particular product in question. Thus, for example, where the product is a polypeptide or protein, the production of this may be monitored by general assay

25 techniques such as enzyme-linked immunoabsorbent assay or immunoradiometric assay adapted for use with the particular polypeptide or protein.

30 Where in the process according to the invention it is desired to isolate the cell product obtained, this may be achieved using conventional separation and purification techniques. Thus, for example, where the product is secreted by the cells into the medium it may be separated from the cells using techniques such as centrifugation and filtration and then further purified using, for example, affinity purification techniques, such as affinity

35 chromatography. Where the product is not secreted by the cells, the above methods may still be used, but after the cells have first been lysed to release the product.

### BRIEF DESCRIPTION OF THE DRAWINGS

5 The invention is now described by way of illustration only in the following Examples which refer to the accompanying diagrams in which:

Figures 1-4 show the growth of mouse hybridoma cells in the presence of tropolone and various other chelators,

10 Figures 5 and 6 show the growth of mouse NS/O cells in the presence of tropolone.

### DESCRIPTION OF SPECIFIC EMBODIMENTS

15 The following Examples illustrate the invention.

#### EXAMPLE 1

20 A mouse hybridoma cell line previously subcultured in a serum-free medium containing 1 $\mu$ g/ml human transferrin was centrifuged and resuspended in transferrin-free medium twice. Cells were finally resuspended at a density of  $1.5 \times 10^5$  cells/ml in transferrin-free growth medium containing 0.1mg/l ferric ammonium citrate.

25 100 x concentrates of the iron chelators to be tested (8-hydroxyquinoline, tropolone, mimosine, maltol or picolinic acid) were prepared in water and filter sterilised. 10 $\mu$ l of each iron chelator was dispersed into wells of a 24 well costar plate and then 1ml of cell suspension added.

30 Acetylacetone was prepared as a 0.05 M stock in ethanol and 2 $\mu$ l was dispersed into tissue culture wells, followed by 1ml of cell suspension. Control wells contained either 10 $\mu$ l water (negative control) or 10 $\mu$ l of 100  $\mu$ g/ml human transferrin solution (positive control).

35 Plates were incubated for 3 days in a humidified incubator under a 5% CO<sub>2</sub> - 95% air atmosphere at 36.5°C under static conditions.

After 3 days samples of dispersed cell suspensions from individual wells were analysed using a Coulter Multisizer to determine cell concentration.

5      Figure 1A shows 3 $\mu$ M tropolone to be as effective as 1 $\mu$ g/ml of human transferrin at supporting cell growth in the presence of 0.36 $\mu$ M iron ( $\equiv$  0.1mg/l ferric ammonium citrate). Other lipophilic chelators at concentrations of 0.03 - 3 $\mu$ M did not support growth of cells in the absence of transferrin.

10     Figure 1B shows 5 $\mu$ M tropolone to be effective at supporting cell growth, whereas 100 $\mu$ M acetylacetone and 50 $\mu$ M picolinic acid were much less effective. These concentrations of picolinic acid and acetylacetone were chosen as the optimum from a previous experiment (data not shown).

15     All media contained 0.1 mg/l ferric ammonium citrate.

## EXAMPLE 2

20     **Methods**

A mouse hybridoma cell line, previously subcultured in serum free medium containing human transferrin, was centrifuged and resuspended at 1.5 x 10<sup>5</sup> cells/ml in either transferrin-free or transferrin-containing serum-free medium. All media contained 0.1, 1, or 10 mg/l of added ferric ammonium citrate. The flasks were gassed in 5% CO<sub>2</sub> - 95% air atmosphere, sealed and incubated either static or on an orbital reciprocal shaking platform (120 rpm) at 36.5°C for 3 days. Samples were then removed and cell concentration was determined by haemocytometry.

30     **Results**

Figure 2A shows that increasing concentrations of ferric ammonium citrate up to 10mg/l support increasing cell concentrations in transferrin-free medium in static culture. However, Figure 2B demonstrates that in agitated culture (reciprocal shaking platform) that ferric ammonium citrate concentrations of >1mg/l are toxic in both the presence or absence of transferrin.

**EXAMPLE 3**

5 A mouse hybridoma cell line was subcultured in a proprietary serum-free medium containing 1mg/l human transferrin and 0.01mg/l ferric ammonium citrate (Figure 3b), or a proprietary protein-free medium containing 5 $\mu$ M tropolone and 0.1mg/l ferric ammonium citrate (Figure 3a). Agitated, sparged fed-batch fermentations of the cell line in each medium were  
10 carried out.

Figure 3a and Figure 3b demonstrate that similar cell growth and production characteristics are seen using either tropolone (Fig 3a) or transferrin (Fig 3b) in an agitated, sparged fermenter system.  
15

**EXAMPLE 4**

20 A mouse hybridoma cell line was subcultured in transferrin-free medium containing 0.1mg/l ferric ammonium citrate and 5 $\mu$ M tropolone. Cells were centrifuged and resuspended in medium containing 0.01mg/l ferric ammonium citrate and 5 $\mu$ M tropolone at a density of  $1.5 \times 10^5$  cells/ml in T-25 flasks. Extra ferric ammonium citrate was added to flasks to create a concentration range from 0.01 - 2mg/l. Flasks were gassed with an atmosphere of 5% CO<sub>2</sub> - 95% air and incubated on an orbital shaking platform (120 rpm) at 36.5°C for 3 days.  
25

After 3 days samples were withdrawn from flasks and cell concentration determined using a Coulter multisizer.  
30

**Results**

35 The cell concentration after 3 days growth is a combined function of iron concentration, cell growth rate and maximum biomass. Hence although maximum biomass is obtained in the range 0.075 - 1mg/l ferric ammonium citrate (growth yield is  $3.3 \times 10^7$  cells/ $\mu$ g ferric ammonium citrate - data not shown), maximum growth rate (Figure 4) is seen at 0.15 - 0.5mg/l ferric ammonium citrate.

EXAMPLE 5

The efficacy of using tropolone as a transferrin replacement was further investigated using recombinant GS-myeloma cell lines [mouse NS/O] expressing humanised antibodies using the glutamine synthetase (GS) expression system, [Bebbington *et al.*, Bio/Technology, 10, 169--175; European Patent Specification No. 256055]. Three recombinant cell lines producing different antibodies were grown in suspension culture in media containing 0.2mg/l ferric ammonium citrate and either 5 $\mu$ M tropolone or 1mg/l transferrin. The growth rates were similar in either medium as was the peak viable cell concentration. For all three cell lines the antibody concentration at the end of the profile was similar when transferrin was replaced by tropolone (see Table 1). In the absence of either tropolone or transferrin but in the presence of 0.2mg/l ferric ammonium citrate myeloma cells failed to thrive and died within 48 hours.

TABLE 1

20

Growth and Productivity of NSO Cell Lines in Medium Containing Tropolone

	TRANSFERRIN		TROPOLONE	
	PEAK CELL DENSITY ( $\times 10^6$ /ml)	ANTIBODY TITRE (mg/l)	PEAK CELL DENSITY ( $\times 10^6$ /ml)	ANTIBODY TITRE (mg/l)
Cell line A	1.30	438	1.51	420
Cell line B	1.46	301	1.49	241
Cell line C	2.62	29	3.17	32

25

EXAMPLE 6

A mouse myeloma cell line [GS-NSO, see Example 5] was subcultured in a transferrin-free medium containing 0.2mg/l ferric ammonium citrate and 5 $\mu$ M tropolone. Cells were centrifuged and resuspended in a protein-free

medium [LS1] containing 0.2 mg/l ferric ammonium citrate and 5 $\mu$ M tropolone at a density of  $2 \times 10^5$  cells/ml in shake flasks. Flasks were gassed with an atmosphere of 5% CO<sub>2</sub> - 95% air and incubated on an orbital shaking platform (120 rpm) at 36.5°C.

5

Figure 5 shows the resulting cell growth.

The LS1 medium additionally contained 2-hydroxypropyl- $\beta$ -cyclodextrin [HPB; 1.2g/l] complexed with cholesterol and fatty acids [prepared before addition to LS1 by dissolving HPB (0.6mg/l) in water and adding to an equal volume of a supplement containing cholesterol and the fatty acids previously dissolved in absolute alcohol, then agitating for 3 hours prior to centrifugation and filtering]. As a control the same cells were grown in LS1 medium supplemented with cholesterol and fatty acids and containing 0.2mg/l ferric ammonium citrate and 5 $\mu$ M tropolone but using bovine serum albumin [BSA] in place of the HPB. Figure 5 shows that tropolone is able to support the growth of both cultures and also that 2-hydroxypropyl- $\beta$ -cyclodextrin is an effective replacement for bovine serum albumin as a carrier for cholesterol and fatty acids.

10

Figure 6 shows the growth of the same myeloma cell line in a 5L airlift fermenter using LS1 medium containing 0.2mg/l ferric ammonium citrate and 5 $\mu$ M tropolone.

15

20

CLAIMS

- 5        1. A nutrient animal cell culture medium comprising assimilable sources of carbon, nitrogen, amino acids, inorganic ions, trace elements and optionally lipids and growth promoters or regulators in admixture with 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof.
- 10      2. A medium according to Claim 1 wherein the 2-hydroxy-2,4,6-cycloheptatrien-1-one or derivative thereof is present in an excess molar concentration to the iron present.
- 15      3. A medium according to Claim 2 wherein the 2-hydroxy-2,4,6-cycloheptatrien-1-one or derivative thereof and iron are present at a molar ratio of around 5 to 1 to around 70 to 1.
- 20      4. A medium according to any of the preceding claims for the continuous growth of animal cells.
- 25      5. A medium according to Claim 4 wherein the animal cell is a mammalian cell.
- 30      6. A medium according to Claim 5 wherein the mammalian cell is a lymphoid cell.
- 35      7. A medium according to Claim 6 wherein the lymphoid cell is a myeloma cell.
8. A protein-free animal cell culture medium according to any of the preceding claims.
9. A process for obtaining an animal cell product by cell culture which comprises the steps of (1) culturing animal cells which produce said product in a nutrient culture medium comprising assimilable sources of carbon, nitrogen, amino acids, iron and other inorganic ions, trace elements and optionally lipids and growth promoters or regulators in admixture with 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative

thereof, (2) continuing the culture until said product accumulates and  
(3) recovering said product.

1/5




FIG. 1A




FIG. 1B

2/5

## STATIC T-FLASK CULTURES




FIG. 2A

## SHAKING T-FLASK CULTURES




FIG. 2B

**SPARGED FERMENTATIONS OF THE SAME  
HYBRIDOMA CELL LINE IN EITHER PROTEIN-FREE  
MEDIUM WITH TROPOLONE OR MEDIUM  
CONTAINING TRANSFERRIN**

**PROTEIN-FREE MEDIUM CONTAINING TROPOLONE**




FIG. 3a

**MEDIUM CONTAINING TRANSFERRIN**




FIG. 3b

—●— cells/ml   —◆— mg/l (ProAnamab)

4/5

GROWTH OF HYBRIDOMA CELL LINE ON LIMITING  
CONCENTRATIONS OF FERRIC AMMONIUM CITRATE IN PROTEIN-FREE  
MEDIUM WITH 5 $\mu$ M TROPOLONE




FIG. 4

5/5

## GROWTH OF A GS-NSO IN PROTEIN-FREE MEDIUM SUSPENSION CULTURE




FIG. 5

## GROWTH OF A GS-NSO CELL LINE IN PROTEIN-FREE MEDIUM 5L AIR LIFT




FIG. 6

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/01572

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 C12N5/02

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.C1. 5	C12N

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP,A,0 274 445 (MEDI-CULT AS) 13 July 1988 see the whole document ----	
A	FILE SERVER STN KARLSRUHE, FILE MEDLINE ABSTRACT NO.88083462 & EUR J HAEMATOL, (1987 OCT),39(4),318-25 FORSBEC ET AL: 'VARIATION IN IRON ACCUMULATION, TRANSFERRIN MEMBRANE BINDING AND DNA SYNTHESIS IN THE K-562 AND U-937 CELL LINES INDUCED BY CHELATORS AND THEIR IRON COMPLEXES' see abstract -----	

<sup>o</sup> Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
08 OCTOBER 1993	15. 10. 93
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer SITCH W.D.C.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9301572  
SA 77289

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 08/10/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0274445	13-07-88	AU-B-	596491	03-05-90
		AU-A-	1011588	14-07-88
		DE-A-	3882540	02-09-93
		JP-A-	63279786	16-11-88
		US-A-	5045467	03-09-91
		US-A-	5045454	03-09-91